Individual and Bivalent Vaccines Based on Alphavirus Replicons Protect Guinea Pigs against Infection with Lassa and Ebola Viruses

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Virology

• Publication date

  2001-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.75.23.11677-11685.2001PMID 11689649PMCID PMC114754
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serology and virulence diversity among Old-World arenaviruses, and the relevance to vaccine development

  2005cited by this paper
• Development of a preventive vaccine for Ebola virus infection in primates

  2000cited by this paper
• Vaccination of Macaques against Pathogenic Simian Immunodeficiency Virus with Venezuelan Equine Encephalitis Virus Replicon Particles

  2000cited by this paper
• Effective Vaccine for Lassa Fever

  2000influential reference
• Lassa fever imported to England.

  2000cited by this paper
• Role of Dendritic Cell Targeting in Venezuelan Equine Encephalitis Virus Pathogenesis

  2000cited by this paper
• Lassa fever, case imported to Germany.

  2000cited by this paper
• Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus.

  2000influential reference
• Pathogenesis of experimental Ebola virus infection in guinea pigs.

  1999cited by this paper
• Lassa fever: implications of T-cell immunity for vaccine development.

  1999cited by this paper
• Immunization for Ebola virus infection

  1998cited by this paper
• Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.

  1998cited by this paper
• Processing of the Ebola virus glycoprotein by the proprotein convertase furin.

  1998cited by this paper
• DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge.

  1998cited by this paper
• Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.

  1997influential reference
• A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge

  1996cited by this paper
• Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins.

  1995cited by this paper
• The emergence of new virus diseases: an overview

  1994cited by this paper
• Cross-protection against lymphocytic choriomeningitis virus mediated by a CD4+ T-cell clone specific for an envelope glycoprotein epitope of Lassa virus

  1993cited by this paper
• Death after Pichinde virus infection in large and small strain 13 guinea pigs.

  1993cited by this paper
• Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone.

  1991cited by this paper
• Preliminary report: isolation of Ebola virus from monkeys imported to USA

  1990cited by this paper
• New Generation Vaccines

  1990cited by this paper
• Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus.

  1989influential reference
• Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene.

  1989cited by this paper
• Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection.

  1988influential reference
• A prospective study of the epidemiology and ecology of Lassa fever.

  1987cited by this paper
• Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever.

  1987cited by this paper
• Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease.

  1987cited by this paper
• Protection of lassa virus‐infected guinea pigs with lassa‐immune plasma of guinea pig, primate, and human origin

  1983cited by this paper
• Pathogenesis of Lassa virus infection in guinea pigs

  1982cited by this paper
• Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire.

  1977cited by this paper
• Lassa Virus Isolation from Mastomys natalensis Rodents during an Epidemic in Sierra Leone

  1974cited by this paper
• Computers and future music.

  1974cited by this paper
• Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings.

  1970cited by this paper
• Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease.

  1970cited by this paper

• Infusion of neutralization into Lassa vaccine design.

  2025cites this paper
• Lassa virus protein–protein interactions as mediators of Lassa fever pathogenesis

  2025cites this paper
• Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer

  2025cites this paper
• Current perspectives on vaccines and therapeutics for Lassa Fever

  2024cites this paper
• Single-Dose Immunogenic DNA Vaccines Coding for Live-Attenuated Alpha- and Flaviviruses

  2024cites this paper
• Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease

  2024cites this paper
• Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control

  2024cites this paper
• Vaccine Candidates against Arenavirus Infections

  2023cites this paper
• The potential epidemic threat of Ebola virus and the development of a preventive vaccine

  2023cites this paper
• Rise of the RNA machines – self-amplification in mRNA vaccine design

  2023cites this paper
• Therapeutic and prophylactic applications of self-replicating RNA viruses

  2022cites this paper
• VaxCelerate II: Rapid development of a self-assembling vaccine VaxCelerate II: Rapid development of a self-assembling vaccine for Lassa fever for Lassa fever

  2022cites this paper
• A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever.

  2022cites this paper
• PROSPECTS OF LASSA FEVER CANDIDATE VACCINES

  2022cites this paper
• Understanding Immune Responses to Lassa Virus Infection and to Its Candidate Vaccines

  2022cites this paper
• Applications of self-replicating RNA.

  2022cites this paper
• Lassa Virus Countermeasures.

  2022cites this paper
• Expression and Immunogenicity of Recombinant African Swine Fever Virus Proteins Using the Semliki Forest Virus

  2022cites this paper
• [Review of candidate vaccines for the prevention of Lassa fever].

  2021cites this paper
• ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge

  2021cites this paper
• MMV-db: vaccinomics and RNA-based therapeutics database for infectious hemorrhagic fever-causing mammarenaviruses

  2021cites this paper
• Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer

  2021cites this paper
• Обзор кандидатных вакцин для профилактики лихорадки Review of candidate vaccines for the prevention of Lassa fever

  2021cites this paper
• ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge

  2021cites this paper
• Prothrombin Time, Activated Partial Thromboplastin Time, and Fibrinogen Reference Intervals for Inbred Strain 13/N Guinea Pigs (Cavia porcellus) and Validation of Low Volume Sample Analysis

  2020cites this paper
• Alphavirus-based vaccines.

  2020cites this paper
• Arenavirus

  2020cites this paper
• The Arenaviridae

  2020cites this paper
• Bivalent Junin & Machupo experimental vaccine based on alphavirus RNA replicon vector.

  2020cites this paper
• Inter-Lineage Variation of Lassa Virus Glycoprotein Epitopes: A Challenge to Lassa Virus Vaccine Development

  2020influential citation
• Hemorrhagic Fever-Causing Arenaviruses: Lethal Pathogens and Potent Immune Suppressors

  2019cites this paper
• Vaccine platforms for the prevention of Lassa fever

  2019cites this paper
• A review of Lassa fever vaccine candidates.

  2019cites this paper
• Lassa virus diversity and feasibility for universal prophylactic vaccine

  2019cites this paper
• A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs

  2019cites this paper
• Attenuated Replication of Lassa Virus Vaccine Candidate ML29 in STAT-1-/- Mice

  2019influential citation
• Novel DNA-launched Venezuelan equine encephalitis virus vaccine with rearranged genome.

  2019cites this paper
• Understanding Molecular Pathogenesis with Chikungunya Virus Research Tools.

  2019cites this paper
• Current research for a vaccine against Lassa hemorrhagic fever virus

  2018cites this paper
• Hemorrhagic Fever-Causing Mammarenaviruses Chapter 21 HEMORRHAGIC FEVER-CAUSING MAMMARENAVIRUSES

  2018cites this paper
• Improving the Breadth of the Host’s Immune Response to Lassa Virus

  2018cites this paper
• Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model

  2018cites this paper
• Pre-clinical development of a vaccine against Lassa fever.

  2018cites this paper
• Current research for a vaccine against Lassa hemorrhagic fever virus

  2018cites this paper
• Современное состояние разработки вакцин для специфической профилактики геморрагических лихорадок, вызываемых аренавирусами

  2018cites this paper
• Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development

  2018cites this paper
• Chimpanzee adenoviral vectors as vaccines for outbreak pathogens

  2017cites this paper
• Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins

  2017cites this paper
• Plasmid DNA launches live-attenuated Japanese encephalitis virus and elicits virus-neutralizing antibodies in BALB/c mice.

  2017cites this paper
• Vaccine platforms to control Lassa fever

  2016cites this paper
• Essais précliniques sur un vaccin contre la fièvre de Lassa

  2016cites this paper
• Recent advances in the development of vaccines for Ebola virus disease.

  2016cites this paper
• Structure-function relationship of the mammarenavirus envelope glycoprotein

  2016cites this paper
• DNA-launched live-attenuated vaccines for biodefense applications

  2016cites this paper
• Evasion and Resistance of Host Antiviral Defense pathways by Alphaviruses

  2016cites this paper
• Replicon RNA Viral Vectors as Vaccines

  2016influential citation
• pKarp47 DNA Vaccination in Cynomolgus Protective Immune Responses Induced by A Nonhuman Primate Scrub Typhus Model:

  2015cites this paper
• Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

  2015cites this paper
• Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever

  2015cites this paper
• A Nonhuman Primate Scrub Typhus Model: Protective Immune Responses Induced by pKarp47 DNA Vaccination in Cynomolgus Macaques

  2015cites this paper
• Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.

  2015cites this paper
• Global Virology I - Identifying and Investigating Viral Diseases

  2015cites this paper
• RNA-based viral vectors

  2015cites this paper
• Short report Open Access

  2015cites this paper
• Dynamics of adaptive immunity during Lassa virus infection and a proposed mechanism for immune impairment

  2015cites this paper
• Research efforts to control highly pathogenic arenaviruses: a summary of the progress and gaps.

  2015cites this paper
• Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus.

  2015cites this paper
• A Recombinant Vesicular Stomatitis Virus-Based Lassa Fever Vaccine Protects Guinea Pigs and Macaques against Challenge with Geographically and Genetically Distinct Lassa Viruses

  2015cites this paper
• DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice.

  2014cites this paper
• Arenaviruses: Lassa Fever, Lujo Hemorrhagic Fever, Lymphocytic Choriomeningitis, and the South American Hemorrhagic Fevers

  2014cites this paper
• Novel Technologies for Vaccine Development

  2014influential citation
• Alphavirus Replicon Vectors for Prophylactic Applications and Cancer Intervention

  2014cites this paper
• Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors

  2014cites this paper
• VaxCelerate II: Rapid development of a self-assembling vaccine for Lassa fever

  2014cites this paper
• A tetravalent alphavirus-vector based dengue vaccine provides effective immunity in an early life mouse model.

  2014cites this paper
• Characterization of alphavirus replicon particle based vaccines and adjuvants in a neonatal murine model

  2014cites this paper
• Перспективы разработки и применения вакцин на основе РНК-репликона вируса венесуэльского энцефаломиелита лошадей против особо опасных вирусных инфекций

  2014cites this paper
• Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses.

  2013cites this paper
• Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation

  2013cites this paper
• Vaccination Strategies against Highly Pathogenic Arenaviruses: The Next Steps toward Clinical Trials

  2013cites this paper
• Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based Semliki Forest virus replicon vectors.

  2013cites this paper
• The search for animal models for Lassa fever vaccine development

  2013cites this paper
• Pathogenic Old World Arenaviruses

  2013cites this paper
• Cellules NK et fièvres hémorragiques virales : étude de leur rôle dans la mise en place des réponses immunes et dans la pathogenèse lors de l'infection par les virus Lassa et Ebola

  2013cites this paper
• Development and evaluation of a replicon particle vaccine expressing the E2 glycoprotein of bovine viral diarrhea virus (BVDV) in cattle

  2013cites this paper
• Minus-Strand RNA Viruses

  2012cites this paper
• Summary and Perspectives

  2012cites this paper
• Biodefense Research Methodology and Animal Models, Second Edition

  2012cites this paper
• Animal models of Rift Valley fever virus infection.

  2012cites this paper
• [Arenavirus infections].

  2012cites this paper
• Mouse Models for Filovirus Infections

  2012cites this paper
• Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model.

  2012cites this paper
• Advanced Vaccine Candidates for Lassa Fever

  2012influential citation
• Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers.

  2012influential citation
• Use of the Syrian Hamster as a New Model of Ebola Virus Disease and Other Viral Hemorrhagic Fevers

  2012cites this paper
• Alphavirus replicon vaccines

  2012cites this paper
• Arenavirus reverse genetics: New approaches for the investigation of arenavirus biology and development of antiviral strategies

  2011cites this paper
• Development of efficacious replicon particle vaccines for swine influenza virus

  2011cites this paper
• Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection.

  2011cites this paper
• Filovirus vaccines.

  2011cites this paper